Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZASCLER
2024-511658-28-01Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Bezafibrate + ursodeoxycholic acid with Placebo + ursodeoxycholic acid (2 arms). Primary endpoint: Primary composite response at month 24. Planned start Sep 2024; status: authorised.
02
Drugs
bezafibrate
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2024-511658-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511658-28-01.